Skip to main content

Advertisement

SpringerLink
Log in

Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The presence of antiphospholipid antibodies has been reported in a large variety of patients with malignancies. Many case reports and reviews have appeared indicating that the presence of the antiphospholipid antibodies is related to thrombotic associations with the antiphospholipid syndrome (APS) in a proportion of these patients. We investigated the frequency of the thrombotic manifestations in 58 patients demonstrating antiphospholipid antibodies and with a history of neoplasia, including haematologic and lymphoproliferative malignancies. Antiphospholipid antibodies were detected by clotting assay [lupus anticoagulant (LAC)] or by enzyme-linked immunosorbent assay [anticardiolipin antibodies (aCL)] according to the Sapporo criteria. Patients, 39/58, suffered from solid tumours and 19/58 patients from malignant haematologic or lymphoproliferative diseases. One patient was suffering simultaneously from two solid tumours and a malignant lymphoma. Among the patients with solid tumours, 18/39 (46%) patients had thromboembolic complications of the antiphospholipid syndrome. Among the patients with haematologic and lymphoproliferative malignancies, only 6/19 (32%) suffered from thromboembolic complications. There was, however, no relation between the titres of aCL antibodies and the clinical manifestations. The presence, but not the titres, of antiphospholipid antibodies may identify a subset of cancer patients with a high risk of developing thrombotic complications. The frequency of thrombosis, however, is lower in aPL-positive patients with lymphoproliferative and haematological malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wilson WA, Gharavi AE, Koike T et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311

    Article  PubMed  CAS  Google Scholar 

  2. McNeil HP, Chesterman CN, Krilis SA (1999) Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 49:193–280

    Article  Google Scholar 

  3. Shortell CK, Ouriel K, Green RM, Condemi JJ, DeWeese JA (1992) Vascular disease in the antiphospholipid syndrome: a comparison with the patient population with atherosclerosis. J Vasc Surg 15:158–165

    Article  PubMed  CAS  Google Scholar 

  4. Galli M, Luciani D, Bertolini G, Barbui T (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101:1827–1832

    Article  PubMed  CAS  Google Scholar 

  5. Asherson RA (2000) Antiphospholipid antibodies, malignancies and paraproteinemias. J of Autoimmun 15:117–122

    Article  CAS  Google Scholar 

  6. Piette J-C, Cervera R, Levy RA, Nasonov EL, Triplett DA, Shoenfeld Y (2000) The catastrophic antiphospholipid syndrome–Asherson’s syndrome. Ann Med Interne 154:195–196

    Google Scholar 

  7. Trousseau A (1865) Phlegmasia alba dolens. In: Clinique Medical de L’Hotel Dieu de Paris Vol 3 London. The New Sydenham Society, 1865:94

  8. Asherson RA, Cervera R, Piette JC et al (2001) Catastrophic antiphospholipid syndrome. Clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 80:1–23

    Google Scholar 

  9. Yamamoto T, Ito M, Nagata S, Suzuki H, Togawa A, Nagase M, Hishida A (2000) Catastrophical exacerbation of antiphospholipid syndrome after lung adenocarcinoma biopsy. J Rheumatol 27:2035–2037

    PubMed  CAS  Google Scholar 

  10. Soltesz P, Szekanecz Z, Vegh J, Lakos G, Toth L, Szakall S, Veres K, Szegedi G (2000) Catastrophic antiphospholipid syndrome in cancer. Haematologica 30:303–311

    Article  CAS  Google Scholar 

  11. Genvresse I, Buttgereit F, Späth-Schwalbe E, Ziemer S, Eucker J, Possinger K (2000) Arterial thrombosis associated with anticardiolipin and anti-β2-glycoprotein-I antibodies in patients with non-Hodgkin’s lymphoma: a report of two cases. Eur J Haematol 65:344–347

    Article  PubMed  CAS  Google Scholar 

  12. Faiderbe S, Chagnaud JL, Charrier MC et al (1991) Antibodies directed against lipid membrane components in sera of patients with malignant tumours. Cancer Detec Prev 15:199–203

    PubMed  CAS  Google Scholar 

  13. Bessis D, Sotto A, Viaid JP, Berard M, Civana AJ, Boffa M (1995) Trousseau’s syndrome with non-bacterial thrombotic endocarditis: pathogenetic role of antiphospholipid syndrome. Am J Med 98:511–513

    Article  PubMed  CAS  Google Scholar 

  14. Bick RL (2003) Cancer-associated thrombosis. N Engl J Med 349:109–111

    Article  PubMed  CAS  Google Scholar 

  15. Brandt JT, Triplett DA, Alving B, Scharrer I (1995) Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 74:1185–1190

    PubMed  CAS  Google Scholar 

  16. Mackie IJ, Donohoe S, Machin SJ (2000) Lupus anticoagulant measurement. In: Khamashta MA (ed). Hughes syndrome. Antiphospholipid syndrome. Springer, Berlin Heidelberg New York, pp 214–225

    Google Scholar 

  17. Triplett DA, Stocker KF, Unger GA (1993) The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 70:925–931

    PubMed  CAS  Google Scholar 

  18. Thiagarajan P, Pengo V, Shapiro SS (1986) The use of the dilute Russel viper venome time for the diagnosis of lupus anticoagulants. Blood 68:869–874

    PubMed  CAS  Google Scholar 

  19. Harris EN, Pierangeli SS (2002) Revisiting the anticardiolipin test and its standardization. Lupus 11:269–275

    Article  PubMed  CAS  Google Scholar 

  20. Tan EM, Cohen AS, Fries JF (1982) The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    PubMed  CAS  Google Scholar 

  21. Campbell AL, Pierangeli SS, Wellhausen S, Harris EN (1995) Comparison of the effect of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 73:529–534

    PubMed  CAS  Google Scholar 

  22. Meroni PL, Raschi E, Camera M, Testoni C, Nicoletti F, Tincani A (2000) Endothelial activation by aPL. A potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 15:237–240

    Article  PubMed  CAS  Google Scholar 

  23. Dobado-Berrios PM, Lopez-Pedreda C, Velazco F, Cuadrado MJ (2001) The role of tissue factor in the antiphospholipid syndrome. Arthritis Rheum 44:2467–2476

    Article  PubMed  CAS  Google Scholar 

  24. Francis JL, Biggerstaff J, Amirkhosravi A (1998) Hemostasis and malignancy. Semin Thromb Hemost 24:93–109

    Article  PubMed  CAS  Google Scholar 

  25. Zuckerman E, Toubi E, Golan T et al (1995) Increased thromboembolic incidence in anticardiolipin-positive patients with malignancy. Br J Cancer 72:447–451

    PubMed  CAS  Google Scholar 

  26. Yoon KH, Wong A, Shakespeare T, Sivalingham P (2003) High prevalence of the antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus 12:112–116

    Article  PubMed  CAS  Google Scholar 

  27. Schved JF, Dupuy-Fons C, Biron C et al (1994) A prospective epidemiological study of the occurrence of antiphospholipid antibody; the Montpelier Antiphospholipid (MAP) Study. Haemostasis 24:175–182

    PubMed  CAS  Google Scholar 

  28. Jude B, Goudermand J, Dolle I et al (1988) Lupus anticoagulant: a clinical study of 100 cases. Clin Lab Haematol 10:41–51

    PubMed  CAS  Google Scholar 

  29. Stasi R, Stipa E, Masi M, Oliva F, Sciarra A, Perrotti A, Zaccari G, Papa G (1993) Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin’s lymphoma. Thromb Haemost 70:568–572

    PubMed  CAS  Google Scholar 

  30. Lossos IS, Bogomolski-Yahalom V, Hatzner Y (1998) Anticardiolipin antibodies in acute myeloid leukemia: prevalence and clinical significance. Am J Haematol 57:139–143

    Article  CAS  Google Scholar 

  31. Lechner K, Pabinger-Fasching I (1985) Lupus anticoagulants and thrombosis. A study of 25 cases and review of the literature. Haemostasis 15:254–262

    PubMed  CAS  Google Scholar 

  32. Rosove MH, Brewer PM (1992) Antiphospholipid thrombosis: clinical course after the first thrombotic events in 70 patients. Ann Intern Med 117:303–308

    PubMed  CAS  Google Scholar 

  33. Vianna JL, Khamashta MA, Ordi-Ros J et al (1994) Comparison of the primary and secondary antiphospholipid syndrome: a European multicentric study of 114 patients. Am J Med 96:3–9

    Article  PubMed  CAS  Google Scholar 

  34. Liozon E, Loustaud V, Jauberteau MO, Jaccard A, Soria P, Bordessoule D, Julia A, Vidal E (2001) Non-simultaneous malignant lymphoma and antiphospholipid syndrome: 4 cases. Rev Med Interne 22:360–370

    Article  PubMed  CAS  Google Scholar 

  35. Sciarra A, Staai R, Stipa B et al (1995) Antifosfolipid prevalenza, significato clinico e correlazione con I livell di citochine nella leucemia mieloice e mel linfomanon-Hodgkin. Recentl Prog Med 86:57–62

    CAS  Google Scholar 

  36. Genvresse I, Lüftner D, Späth-Schwalbe E, Buttgereit F (2002) Prevelance and clinical significance of anticardiolipin and anti-β2-glycoprotein-I antibodies in patients with non-Hodgkin’s lymphoma. Eur J Haematol 68:84–90

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine III, University Hospital, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany

    Wolfgang Miesbach, Inge Scharrer & Ronald Asherson

Authors
  1. Wolfgang Miesbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Inge Scharrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ronald Asherson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang Miesbach.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miesbach, W., Scharrer, I. & Asherson, R. Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies. Clin Rheumatol 25, 840–844 (2006). https://doi.org/10.1007/s10067-005-0181-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-005-0181-2

Keywords

Search

Navigation